- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Replimune Group, Inc. is seeking regulatory approval from the FDA for its therapies.
The FDA issued a Complete Response Letter regarding the RP1 BLA to Replimune Group, Inc. on August 7, 2025.
11 reports, 3 independent
Updated Sep 8
Mostly repetition
- Reports
- 11
- Developments
- 3
- Repetition
- 73%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA issued a Complete Response Letter regarding the RP1 BLA to Replimune Group, Inc. on August 7, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Company allegedly failed to address study design concerns in its regulatory application.1 source
FDA review process concerns Replimune's BLA.1 source
FDA issues CRL for RP1 BLA, requiring the company to find an expeditious path forward.1 source
Keep exploring
The entities involved
Related events
- FDA accepted Milestone's response to the Complete Response Letter (CRL).
- FDA issued a Complete Response Letter (CRL) regarding Disc Medicine, Inc.'s bitopertin program.
- FDA approval enables commercial opportunity involving CBRE Group.
- The FDA is involved in regulating drug approvals for GLP-1 Receptor Agonists.
- Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.
Coverage
Newest first; wire copies grouped- pr-inside.com
- prnewswire.com
- pr-inside.com
- pr-inside.com
- pr-inside.com
- GlobeNewswireReplimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage bio
- GlobeNewswireReplimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc